longbridge

Junshi Biosciences Announces Acceptance of the Supplemental Application for Toripalimab plus Chemotherapy as Perioperative Treatment for Resectable Stage Ⅱ-Ⅲ NSCLC

Unusual Whales
The NMPA has approved the supplemental application for the use of Toripalimab in combination with chemotherapy as a perioperative treatment for resectable stage Ⅱ-Ⅲ NSCLC. This decision allows for the treatment to be used in patients with these specific stages of non-small cell lung cancer.

Source: Unusual Whales The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

© 2026 Longbridge｜Terms of ServicePrivacy Policy